Mirati Therapeutics, a targeted oncology company based in San Diego, California, has promoted Vice President of Finance Jamie A. Donadio to Senior Vice President and Chief Financial Officer. In his new role, Donadio will be responsible for all corporate finance and accounting activities for the company.
“Since joining the company in 2013 Donadio has been instrumental in building out our finance capabilities. As our pipeline progresses and our business continues to grow, sound financial planning and discipline will become even more important as we work to advance our rich pipeline of targeted cancer therapies,” stated Charles M. Baum, CEO of Mirati.
Prior to Mirati, Donadio spent 12 years at Amylin Pharmaceuticals, most recently serving as Senior Director of Finance, where he was responsible for corporate finance activities including financial planning and analysis, treasury and capital formation strategy.
In January, Mirati appointed Marcy Graham as Vice President, Investor Relations (IR) and Corporate Communications.